Bristol Myers Squibb just made one of the largest enterprise AI bets in pharmaceutical history, partnering with Anthropic to deploy the Claude family of AI models across its entire global operation. This isn’t a limited pilot or a flashy proof-of-concept. It’s a full-scale deployment touching over 30,000 employees.
The deal positions Claude as what BMS is calling an “intelligence layer” throughout the company, handling tasks that range from drug discovery and clinical trial documentation to real-time manufacturing monitoring.
From pilot projects to production pipelines
The partnership follows what BMS describes as a three-year investment in AI technology. That’s notable because it means the company has been building internal infrastructure and governance frameworks well before this announcement.
One of the more interesting technical details is the deployment of Claude Code, Anthropic’s developer-facing tool, which BMS engineering teams will use to standardize and accelerate internal AI development. The explicit goal here is to break down data silos across research, manufacturing, and regulatory teams using AI as the connective tissue.
